14/15 Conduit Street
London W1S 2XJ
Empleados a tiempo completo: 9
|Nombre||Título||Paga||Ejecutado||Año de nacimiento|
|Mr. Gabriele Marco Antonio Cerrone M.B.A., MBA||Founder, Exec. Chairman & Interim CEO||444k||N/A||1972|
|Dr. Andrea Brancale||Scientific Founder||N/A||N/A||N/A|
|Mr. Richard Clarkson Ph.D.||Scientific Founder||N/A||N/A||N/A|
|Mr. Andrew Westwell Ph.D.||Scientific Founder||N/A||N/A||N/A|
|Ms. Keeren Shah||Chief Financial Officer||N/A||N/A||1977|
|Dr. Matthew W. Davis M.D., RPh||Chief Medical Officer & Acting Chief Scientific Officer||N/A||N/A||N/A|
|Prof. Napoleone Ferrara M.D.||Member of Scientific Advisory Board||N/A||N/A||1957|
Tiziana Life Sciences Ltd, a biotechnology company, focuses on the discovery and development of molecules to treat human diseases in oncology and immunology. The company's lead product candidate in immunology is Foralumab (TZLS-401), a human anti-CD3 monoclonal antibody (mAb) for the treatment of Crohn's, graft versus host, ulcerative colitis, multiple sclerosis, type-1 diabetes, inflammatory bowel, psoriasis, and rheumatoid arthritis diseases. It also develops Milciclib (TZLS-201), a small molecule inhibitor of various cyclin-dependent kinases, tropomycin receptor kinases, and Src family kinases controlling cell growth and malignant progression of cancer; and anti- receptor (IL6R) mAb (TZLS-501), a fully human monoclonal antibody for the treatment of IL6-induced inflammation and to treat COVID-19 patients. Tiziana Life Sciences Ltd was incorporated in 1998 and is headquartered in London, the United Kingdom.Kingdom.
El ISS Governance QualityScore de Tiziana Life Sciences Ltd, a día N/A, es N/A. Las puntuaciones base son Auditoría: N/A; Tablero: N/A; Derechos de los accionistas: N/A; Compensación: N/A.